Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction Study of BPN14770 and Rosuvastatin in Healthy Adults
NCT07011992Phase 1Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Jul 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zatolmilast in Fragile X syndrome (FXS), sponsored by Shionogi & Co., Ltd. Primary endpoints: Maximum Plasma Concentration of Rosuvastatin at Day 11 and Time to Maximum Plasma Concentration of Rosuvastatin at Day 11. Started Jul 2025; status: completed.
02
Drugs
zatolmilast
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NCT07011992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07011992.